Migraine mutations increase stroke vulnerability by facilitating ischemic depolarizations

Katharina Eikermann-Haerter1, Jeong Hyun Lee, Izumi Yuzawa

  • 1Stroke and Neurovascular Regulation Laboratory, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.

Circulation
|December 7, 2011
PubMed
Abstract

Insights

Familial hemiplegic migraine (FHM) mutations increase stroke risk by making the brain more vulnerable to ischemic events. This heightened susceptibility to brain depolarization leads to larger strokes and worse outcomes.

Area of Science:

  • Neuroscience
  • Genetics
  • Stroke Research

Background:

  • Migraine is a known stroke risk factor, but underlying mechanisms remain unclear.
  • Familial hemiplegic migraine (FHM) serves as a valuable model for common migraine due to shared features and mechanisms.
  • FHM is associated with an increased risk of stroke.

Purpose of the Study:

  • To investigate the impact of FHM type 1 (FHM1) mutations on brain vulnerability to ischemic stroke.
  • To elucidate the cellular and physiological mechanisms linking FHM to stroke risk.

Main Methods:

  • Utilized two FHM1 mutant mouse strains and wild-type controls.
  • Assessed brain activity using anoxic depolarization and peri-infarct depolarizations.
  • Quantified infarct size and neurological outcomes using diffusion-weighted MRI and laser speckle flowmetry.
  • Investigated the effect of a glutamate receptor antagonist.

Main Results:

  • FHM1 mutations led to earlier anoxic depolarization and more frequent peri-infarct depolarizations in mutant mice.
  • Mutant mice exhibited rapid infarct core expansion and larger perfusion deficits.
  • Mutant mice required higher cerebral blood flow for survival, leading to infarction with milder ischemia.
  • Mutant mice developed larger infarcts and worse neurological outcomes, which were reduced by glutamate receptor antagonist treatment.

Conclusions:

  • Enhanced susceptibility to ischemic depolarizations, similar to spreading depression, predisposes migraineurs to infarction during mild ischemic events.
  • This mechanism contributes to the increased stroke risk observed in migraineurs.
  • Targeting glutamatergic mechanisms may offer therapeutic potential for stroke prevention in susceptible individuals.

Related Concept Videos

Ischemic Stroke ll: Pathophysiology01:15

Ischemic Stroke ll: Pathophysiology

An ischemic stroke occurs when a cerebral blood vessel becomes obstructed, most often by a thrombus or embolus, interrupting the delivery of oxygen and glucose to brain tissue. Because neurons rely on continuous aerobic metabolism, energy failure begins within minutes of reduced perfusion. The region receiving the least blood flow becomes the infarct core, an area of irreversible cellular death. Surrounding this core lies the penumbra, a zone of hypoperfused but still viable tissue that is...
Ischemic Stroke l: Introduction01:15

Ischemic Stroke l: Introduction

Ischemic stroke is an acute cerebrovascular condition in which blood flow to a brain region is suddenly interrupted, leading to tissue infarction. Neurons depend on continuous oxygen and glucose supply, so even brief reductions in perfusion cause energy failure, ionic imbalance, and irreversible injury. Ischemic strokes are classified into thrombotic and embolic types based on their underlying mechanisms.Thrombotic MechanismsThrombotic stroke develops when a clot forms within a cerebral artery.
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Hemorrhagic Stroke ll: Pathophysiology01:29

Hemorrhagic Stroke ll: Pathophysiology

A hemorrhagic stroke develops when a cerebral blood vessel ruptures, allowing blood to escape into the surrounding brain tissue, as in intracerebral hemorrhage (ICH), or into the subarachnoid space, as in subarachnoid hemorrhage (SAH). Because the skull is a rigid compartment, the sudden presence of extravascular blood rapidly increases intracranial pressure and compresses adjacent neural structures, leading to immediate tissue injury and impaired cerebral perfusion.Mass Effect and Primary...
Hemorrhagic Stroke l: Introduction01:17

Hemorrhagic Stroke l: Introduction

A hemorrhagic stroke is an acute neurological event that occurs when a weakened cerebral blood vessel ruptures, allowing blood to accumulate within or around the brain. The sudden release of blood forms a focal hematoma that increases intracranial pressure, displaces neural tissue, and can obstruct cerebrospinal fluid pathways. These effects may be compounded by intraventricular extension of the hemorrhage, cerebral edema, or compression of adjacent structures, all of which contribute to...
Increased Intracranial Pressure ll: Pathophysiology01:29

Increased Intracranial Pressure ll: Pathophysiology

Increased intracranial pressure (ICP) refers to a potentially life-threatening rise in pressure inside the skull. This usually happens when there is a major change in the volume of brain tissue, blood, or cerebrospinal fluid (CSF) — the three components inside the skull. According to the Monro-Kellie doctrine, if the volume of one component increases, the volumes of the other components must decrease to maintain normal pressure. If this does not happen, ICP rises.The process often begins with...